Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

a second monocentric, prospective, open label pilot study in France of daily dosing of IMA001 in 12 sickle cell disease patients with 3 months of follow-up plus 1 month post dosing.

Next Previous
Trial Profile

a second monocentric, prospective, open label pilot study in France of daily dosing of IMA001 in 12 sickle cell disease patients with 3 months of follow-up plus 1 month post dosing.

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMA 001 (Primary)
  • Indications Sickle cell anaemia
  • Focus Adverse reactions; Pharmacokinetics

Most Recent Events

  • 04 Nov 2025 New trial record
  • 09 Apr 2023 According to the Imalia Media Release, company is conducting in France a second monocentric, prospective, open label pilot study in France of daily dosing of IMA001 in 12 sickle cell disease patients with 3 months of follow-up plus 1 month post dosing.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top